Stockscreener 앱 받기
2.20
2.33%
0.05
전일 마감가:
$2.15
열려 있는:
$2.16
하루 거래량:
462.01K
Relative Volume:
0.46
시가총액:
$106.28M
수익:
-
순이익/손실:
$-97.22M
주가수익비율:
-1.5942
EPS:
-1.38
순현금흐름:
$-82.44M
1주 성능:
-5.98%
1개월 성능:
-14.73%
6개월 성능:
-13.73%
1년 성능:
-92.63%
1일 변동 폭
$2.1476
$2.23
1주일 범위
$2.105
$2.39
52주 변동 폭
$1.15
$33.98
카사바 Stock (SAVA) Company Profile
명칭
Cassava Sciences Inc
전화
512-501-2444
주소
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
SAVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
2.20 | 109.66M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
카사바 Stock (SAVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-26 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-10-08 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-07-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-11-16 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-07-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
| 2021-04-27 | 개시 | B. Riley Securities | Buy |
| 2021-02-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-05-18 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-15 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-01-10 | 재확인 | Maxim Group | Buy |
모두보기
카사바 주식(SAVA)의 최신 뉴스
Published on: 2025-08-20 23:17:10 - beatles.ru
Chart Patterns Forming a Bullish Setup in Cassava Sciences Inc. Equity WarrantPortfolio Gains Summary & Real-Time Market Sentiment Alerts - mustnews.co.kr
Bullish Candlestick Pattern Forms in Cassava Sciences Inc. Equity WarrantEarnings Beat & Trade Opportunity Analysis - beatles.ru
How Cassava Sciences Inc. Equity Warrant stock performs during market volatilityPortfolio Value Report & Weekly High Conviction Ideas - beatles.ru
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire
Cassava Sciences Advances Simufilam for Epilepsy Treatment - TipRanks
Published on: 2025-08-18 07:19:35 - sundaytimes.kr
Cassava Sciences Posts Q2 2025 Earnings: Mixed Results Amid Sector Stability - AInvest
Is It Too Late to Sell Cassava Sciences Inc. Equity WarrantGap Up & Target Return Focused Stock Picks - sundaytimes.kr
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit – SAVA - ACCESS Newswire
Why Cassava Sciences Inc. Equity Warrant stock attracts strong analyst attentionJuly 2025 Fed Impact & Free Community Consensus Stock Picks - mustnews.co.kr
Cassava Sciences Posts Q2 Loss on Pivot - AOL.com
Cassava Reports Q2 2025 Financials Results and Provides Business Update - GlobeNewswire
Elliott Wave Theory Predicts Pullback in Cassava Sciences Inc.2025 Trade Ideas & Daily Growth Stock Tips - thegnnews.com
Cassava Sciences reports Q2 EPS (92c) vs 13c last year - TipRanks
Is Cassava Sciences Inc. Starting a New Uptrend2025 Biggest Moves & Daily Profit Maximizing Trade Tips - thegnnews.com
CASSAVA SCIENCES INC SEC 10-Q Report - TradingView
Cassava Sciences Advances Simufilam Development for TSC-Related Epilepsy and Reports Financial Results for Q2 2025 - Quiver Quantitative
Why is Cassava Sciences Inc. Equity Warrant stock going downTop Earnings Growth Momentum Picks - thegnnews.com
Cassava Sciences Inc. Equity Warrant Stages Intraday Comeback — Trend ChangeValue Investing Picks With Stability Outlined - beatles.ru
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer - GlobeNewswire
Cassava Sciences Boosts Medical Leadership with New CMO Appointment, Analysts Maintain Cautionary Price Target - AInvest
Cassava Sciences appoints Hulihan as Chief Medical Officer - TipRanks
Cassava Sciences appoints Dr. Joseph Hulihan as Chief Medical Officer - MarketScreener
Cassava Sciences' Strategic Hire of Joe Hulihan as CMO: A Catalyst for Accelerated Pipeline Development in Neurodegenerative Therapeutics - AInvest
Cassava Sciences appoints Joseph Hulihan as chief medical officer By Investing.com - Investing.com South Africa
Simufilam reduces tuberous sclerosis-associated seizures - BioWorld MedTech
Cassava Sciences Announces Positive Preclinical Results - TipRanks
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam For Tsc-Related Epilepsy - TradingView
SAVA’s simufilam cuts seizures in TSC mice; first human trial slated H1 2026 | SAVA SEC FilingForm 8-K - Stock Titan
Cassava Sciences Reports Positive Preclinical Results for Simufilam in Tuberous Sclerosis Complex-Related Epilepsy - Quiver Quantitative
Cassava Sciences and Simufilam: A Groundbreaking Opportunity in TSC-Related Epilepsy - AInvest
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy - The Manila Times
What analysts say about Cassava Sciences Inc. Equity Warrant stockInvest like a pro with expert recommendations - Jammu Links News
What is the risk reward ratio of investing in Cassava Sciences Inc. stockTremendous growth opportunities - Jammu Links News
Why is Cassava Sciences Inc. stock attracting strong analyst attentionUncover the best stocks for explosive growth - Jammu Links News
Is Cassava Sciences Inc. stock overvalued or undervaluedMaximize your returns with portfolio optimization - Jammu Links News
What catalysts could drive Cassava Sciences Inc. stock higher in 2025Consistently high returns - Jammu Links News
Cassava Sciences Inc. Equity Warrant Stock Analysis and ForecastTremendous gains - Jammu Links News
Is it the right time to buy Cassava Sciences Inc. stockPhenomenal capital gains - Jammu Links News
What are the technical indicators suggesting about Cassava Sciences Inc. Equity WarrantFree Trading Strategy Suggestions - Jammu Links News
Is it the right time to buy Cassava Sciences Inc. Equity Warrant stockSuperior stock selection - Jammu Links News
Is Cassava Sciences Inc. Equity Warrant stock overvalued or undervaluedMaximize your portfolio’s growth potential - Jammu Links News
What is the dividend policy of Cassava Sciences Inc. stockUnlock exclusive stock market forecasts - Jammu Links News
What makes Cassava Sciences Inc. Equity Warrant stock price move sharplyExponential wealth increase - Jammu Links News
How does Cassava Sciences Inc. compare to its industry peersHigh-profit stock alerts - Jammu Links News
How does Cassava Sciences Inc. generate profit in a changing economyExponentially increasing returns - Jammu Links News
Should I hold or sell Cassava Sciences Inc. Equity Warrant stock in 2025Maximize returns with smart investment plans - Jammu Links News
What drives Cassava Sciences Inc. Equity Warrant stock priceMarket-leading capital gains - Jammu Links News
What are analysts’ price targets for Cassava Sciences Inc. in the next 12 monthsExceptional profit margins - Jammu Links News
What are analysts’ price targets for Cassava Sciences Inc. Equity Warrant in the next 12 monthsCapitalize on emerging market opportunities - Jammu Links News
카사바 (SAVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
카사바 주식 (SAVA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Option Exercise |
1.18 |
50,000 |
59,000 |
71,300 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.86 |
59,800 |
230,828 |
11,500 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.82 |
2,000 |
7,640 |
0 |
0.94%
1.72%
자본화:
|
볼륨(24시간):